U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill medical patients (for specialized target groups only)

A new oral option for patients in the U.S. with acute medical illnesses at risk for thromboembolic complications who are not at high risk of bleeding / Rivaroxaban is the only non vitamin K antagonist oral anticoagulant (NOAC) approved in the U.S for the continuum of venous thromboembolism (VTE) care, from prevention and treatment of initial VTE through extended prevention of recurrent VTE
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news